Active ingredientEverolimusCat. No. P-E143-001CAS 159351-69-6Family · Pharmaceutical analytical standards
Everolimus
An mTOR inhibitor derived from sirolimus (rapamycin): approved in the United States in 2009 for advanced kidney cancer and in 2010 against kidney transplant rejection, it is also used in some breast and neuroendocrine tumours and in coronary stents. This family brings together the active ingredient, pharmacopoeial impurities, labelled standards and other impurities.
Did you know?The rapamycin it derives from comes from a bacterium found in a soil sample collected on Easter Island (Rapa Nui) during a Canadian expedition in 1964-65: the name honours the island.
Go to the active ingredient →Active ingredientEverolimusCat. No. P-E143-001CAS 159351-69-6
Pharmacopoeial impurityEverolimus EP Impurity BCat. No. P-E143-002CAS 1062122-63-7
Pharmacopoeial impurityEverolimus EP Impurity B Lithium Salt (Mixture of E/Z-Isomers)Cat. No. P-E143-003
Pharmacopoeial impurityEverolimus EP Impurity DCat. No. P-E143-004CAS 2760174-96-5
Pharmacopoeial impurityEverolimus EP Impurity ECat. No. P-E143-005CAS 1237826-25-3
Isotopically labelledEverolimus-13C2-d4Cat. No. P-E143-006CAS 1661009-29-5
Isotopically labelledEverolimus-d4Cat. No. P-E143-007CAS 1338452-54-2
ImpurityEverolimus Impurity 1Cat. No. P-E143-008CAS 18928-34-2
ImpurityEverolimus Impurity 2Cat. No. P-E143-009CAS 2607-52-5
ImpurityEverolimus Impurity 3Cat. No. P-E143-010CAS 164162-36-1
Impurity2-Hydroxyethyl trifluoromethanesulfonateCat. No. P-E143-011CAS 108286-01-7
ImpurityDesmethoxy EverolimusCat. No. P-E143-012
Pharmacopoeial impurityEverolimus EP Impurity CCat. No. P-E143-013
ImpurityEverolimus cyclic hemiacetalCat. No. P-E143-015
ImpurityEverolimus Hydrolyzed ImpurityCat. No. P-E143-017CAS 769905-89-7
ImpurityEverolimus Impurity 4Cat. No. P-E143-018CAS 159351-77-6
ImpurityEverolimus Impurity 5Cat. No. P-E143-019CAS 159351-75-4
ImpurityEverolimus Impurity 6Cat. No. P-E143-020
ImpurityEverolimus Impurity 7Cat. No. P-E143-021CAS 201665-18-1
ImpurityEverolimus Impurity 8Cat. No. P-E143-024
ImpurityEverolimus Impurity 9Cat. No. P-E143-025CAS 2402744-97-0
ImpurityEverolimus Impurity 10Cat. No. P-E143-026CAS 2839144-81-7
ImpurityEverolimus O-Ethyl ImpurityCat. No. P-E143-027CAS 1704711-12-5
ImpurityEverolimus O-Silyl ImpurityCat. No. P-E143-028CAS 159351-68-5
ImpurityEverolimus oxepane isomerCat. No. P-E143-029CAS 908340-97-6
ImpurityEverolimus Impurity 11Cat. No. P-E143-030
ImpurityEverolimus Impurity 12Cat. No. P-E143-031CAS 147438-30-0
ImpurityEverolimus Impurity 13Cat. No. P-E143-033
ImpurityEverolimus Ring-Opening Impurity (Mixture of Isomers)Cat. No. P-E143-035CAS 1708118-13-1
ImpurityO-Desmethyl EverolimusCat. No. P-E143-036CAS 745779-75-3No product matches your search.
EDQM standards 2
The official European Pharmacopoeia standards for this family.
Reference substanceEverolimus CRSEDQM code Y0002048Family EverolimusNeed a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.